Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5701786 | Journal of Thoracic Oncology | 2016 | 31 Pages |
Abstract
PD-L1 expression in resected lung adenocarcinomas is frequently observed in the presence of CTL/Th1 microenvironment, in particular in those with KRAS mutations or no common molecular alterations, suggesting that blockade of the PD-1/PD-L1 axis may be a promising treatment strategy to reinstitute active immune response for at least a subset of such patient populations.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Tiffany G. BA, Vicente MD, MPH, Meghan J. MD, Justin F. MD, Emine MD, Hironori MD, PhD, Ling MD, Maria BA, Aaron N. MD, PhD, Eugene J. MD, Michael MD, Jeffrey A. MD, PhD, Mari MD,